文献速递消化道肿瘤与早癌消化内镜消化道出血

转移性结直肠癌近期使用贝伐珠单抗后内镜安全性

Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer.
PubMed 文献 · Gastrointest Endosc · 2025-11-20

本研究基于TriNetX数据库,比较转移性结直肠癌患者近期(≤1个月)使用贝伐珠单抗与其他活性化疗后30天内镜相关穿孔和出血风险。倾向评分匹配后,穿孔风险无显著差异,但贝伐珠单抗组30天术后出血风险显著升高,主要见于治疗性(尤其是胃镜)操作。

要点

  • 近期贝伐珠单抗不增加30天内镜后穿孔风险
  • 贝伐珠单抗与30天术后出血风险升高相关
  • 出血风险升高主要见于治疗性操作,尤其是胃镜

核心结论

  • 近期贝伐珠单抗暴露不增加30天内镜后穿孔风险,但增加出血风险,主要见于治疗性操作。

研究设计与样本

  • 基于TriNetX多国联邦电子健康网络数据库的倾向评分匹配队列研究。
  • 诊断性内镜匹配后n=396,治疗性内镜n=1306,合计n=2100。
  • 采用Kaplan-Meier分析匹配队列30天穿孔和出血风险,并用Cox模型对未匹配队列进行敏感性分析。

关键数值与推荐

  • 近期使用定义为内镜前≤1个月接受贝伐珠单抗。
  • 主要结局为30天内镜后穿孔和30天术后出血。

临床怎么用

  • 近期使用贝伐珠单抗的患者行治疗性内镜(尤其胃镜)时需关注出血风险。
  • 诊断性内镜的出血风险未见显著升高,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Bevacizumab improves metastatic colorectal cancer (mCRC) survival but increases risks including GI perforation. This study compared 30-day postendoscopy (EGD/colonoscopy) perforation and bleeding risks between mCRC patients receiving recent (≤1 month) bevacizumab versus other active chemotherapy. METHODS: TriNetX, a multinational federated electronic health network database, was used to create and analyze 1:1 propensity score-matched cohorts of patients who underwent endoscopy for either diagnostic purposes (n = 396 total postmatch) or therapeutic purposes (n = 1306) as well as combined (n = 2100). Time-to-event analysis on 30-day perforation risk and 30-day postprocedural bleeding was conducted using Kaplan-Meier analysis on matched cohorts as well as adjusted Cox proportional hazards models on unmatched cohorts for sensitivity analysis. RESULTS: Baseline covariates were balanced post matching. No significant difference in 30-day perforation risk was found (Combined: hazard ratio [HR], 0.93; P = .791; Diagnostic: HR, 2.33; P = .143; Therapeutic: HR, 0.96; P = .925). Bevacizumab was associated with a significantly higher 30-day postprocedural bleeding risk in the Combined (matched HR, 1.28; P = .006) and Therapeutic (matched HR, 1.45; P = .001; adjusted HR, 1.46; P < .001) analyses but not in the Diagnostic subgroup (matched HR, 1.03; P = .894; adjusted HR, 0.98; P = .921). CONCLUSIONS: Recent bevacizumab exposure was not associated with increased 30-day postendoscopy perforation risk compared with other active chemotherapy, but was associated with higher bleeding risk, primarily in therapeutic (specifically EGD) procedures.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Sood A, Herman N, Hung CK, et al. Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer. Gastrointest Endosc. 2025. PMID: 41274356. doi:10.1016/j.gie.2025.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。